Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenerative Medical Technology (RMTG) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for Regenerative Medical Technology (RMTG) over the last 8 years, with Q3 2025 value amounting to 33.38%.

  • Regenerative Medical Technology's EBITDA Margin fell 419100.0% to 33.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.44%, marking a year-over-year increase of 33800.0%. This contributed to the annual value of 4.97% for FY2024, which is 258300.0% up from last year.
  • As of Q3 2025, Regenerative Medical Technology's EBITDA Margin stood at 33.38%, which was down 419100.0% from 22.33% recorded in Q2 2025.
  • In the past 5 years, Regenerative Medical Technology's EBITDA Margin registered a high of 21.74% during Q4 2024, and its lowest value of 5454.64% during Q3 2021.
  • For the 5-year period, Regenerative Medical Technology's EBITDA Margin averaged around 610.94%, with its median value being 33.17% (2022).
  • As far as peak fluctuations go, Regenerative Medical Technology's EBITDA Margin crashed by -50601600bps in 2021, and later surged by 54214700bps in 2022.
  • Quarter analysis of 5 years shows Regenerative Medical Technology's EBITDA Margin stood at 185.98% in 2021, then crashed by -138bps to 442.12% in 2022, then soared by 98bps to 10.16% in 2023, then soared by 314bps to 21.74% in 2024, then plummeted by -254bps to 33.38% in 2025.
  • Its EBITDA Margin was 33.38% in Q3 2025, compared to 22.33% in Q2 2025 and 11.9% in Q1 2025.